Tuberculosis is the deadliest infectious disease, and treatments for multidrug-resistant tuberculosis are lengthy and toxic. By analyzing a large international database (N = 7,750), we identified patient risk phenotypes linked to unfavorable outcomes. Factors like HIV infection, age, low BMI, smoking, acid-fast bac...
M. García-Cremades, Jonathon R. Campbell, N. Strydom et al.· Nature Communications· 0 citations
Background: Ethambutol, a longstanding treatment for tuberculosis, lacks comprehensive pharmacokinetic data, particularly regarding covariates affecting exposure and their link to treatment outcomes. Using the largest data to date from Study 31/AIDS Clinical Trials Group A5349, we aimed to characterize ethambutol pharm...
S. Alkhafaji, E. Yang, Kaylee Lee et al.· Journal of Infectious Diseas...· 0 citations
Background/Objectives: Mucosal healing (MH) is a key therapeutic target in inflammatory bowel disease (IBD) associated with sustained remission, reduced hospitalisation, and improved outcomes. Its assessment relies on endoscopic evaluation, which is invasive, costly, and not always feasible. Therapeutic drug monitoring...
A. Homšek Ilić, M. Jovanović, S. Marković et al.· Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
